The positive-strand RNA virus known as hepatitis C virus (HCV) belongs to the family Flaviviridae's genus Hepacivirus. At least six genotypes (gt) of HCV exist, and the polymerase's error-prone nature results in more than 50 subtypes. The host and viral proteases break down the long open reading frame, which encodes the HCV polyprotein, into seven nonstructural (NS) proteins (p7, NS2, NS3, NS4A, NS4B, NS5A, and NS5B) and three structural proteins (the capsid protein core and envelope glycoproteins E1 and E2). While NS3 to NS5B are involved in a membrane-associated RNA replicase complex (RC), NS2 and p7 are required for virus assembly but not RNA replication.NS4A acts as a cofactor for the NS3 serine protease, NS5B is the RNA-dependent RNA polymerase, and NS5A is thought to play important roles in numerous stages of the HCV life cycle. The NS3 protein is made up of a serine protease and an RNA helicase/nucleoside triphosphatase (NTPase).After being administered to HCV-infected cells, NS5A inhibitors quickly reduce the virus' ability to infect cells.
By preventing Kv2.1 function and preventing apoptosis, the HCV protein NS5A prevents the loss of intracellular potassium that would otherwise occur in hepatocytes.
Alpha interferon, Telaprevir, the NS5A inhibitor BMS-790052, and PSI-7977, as well as the combination of lucidone and alpha interferon, all work synergistically to inhibit HCV RNA replication.
| Structure | Cat No. | Product Name | CAS No. | Product Description |
|---|---|---|---|---|
|
V3263 | Dasabuvir (ABT-333) | 1132935-63-7 | Dasabuvir (formerly known as ABT-333; ABT333;trade name Exviera, Viekira Pak, Viekira XR) is a nonnucleoside inhibitor of the RNA-dependent RNA polymerase encoded by the hepatitis C virus (HCV) NS5B gene. |
|
V29312 | Deapioplatycodin D | 78763-58-3 | Deapioplatycodin D is a novel and potent triterpenoid saponin. |
|
V5309 | Deferiprone | 30652-11-0 | Deferiprone (tradename Ferriprox) is novel, potent and orally bioactive iron-chelating drug used for transfusional iron overload clinically. |
|
V52192 | Dehydrojuncusol | 117824-04-1 | Dehydrojuncusol is a potent HCV (hepatitis C virus) virus inhibitor that targets hepatitis C virus NS5A and can inhibit the RNA replication of replicons carrying resistance mutations against NS5A direct-acting antiviral active molecules. |
|
V76304 | Dihydrodehydrodiconiferyl alcohol 9-O-α-L-rhamnopyranoside | 1252572-36-3 | Dihydrodehydrodiconiferyl alcohol 9-O-α-L-rhamnopyranoside (compound 1) is a lignan with anti-HBC activity. |
|
V76307 | Dihydrodehydrodiconiferyl alcohol 9-O-β-D-xylopyranoside | 1015175-06-0 | Dihydrodehydrodiconiferyl alcohol 9-O-β-D-xylopyranoside is an anti-hepatitis B virus (anti-HBV (hepatitis B virus)) agent. |
|
V52090 | FNC-TP | 2457357-99-0 | FNC-TP is the intracellular active form of FNC. |
|
V79501 | FNC-TP trisodium | FNC-TP trisodium is the intracellular active form of FNC. | |
|
V3171 | Glecaprevir | 1365970-03-1 | Glecaprevir (previously called ABT493; A1282576;ABT-493; A-1282576;Mavyret) is a novel and potent inhibitor of thehepatitis C virus nonstructural protein 3/4A protease (HCV NS3/4A) approved as anti-HCV drug in co-formulation with an HCV NS5A inhibitor pibrentasvir. |
|
V3160 | Grazoprevir hydrate | 1350462-55-3 | Grazoprevir hydrate (previously known asMK 5172; MK-5172;MK5172;Zepatier), the mono-hydrated form of grazoprevir, is a second generation inhibitor of HCV (Hepatitis C Virus) NS3/4A Protease and a marketed broad spectrum anti-HCV drug withactivity across genotypes and resistant variants. |
|
V3162 | Grazoprevir potassium salt | 1206524-86-8 | Grazoprevir potassium salt (formerly known asMK-5172; brand name: Zepatier), the potassium salt form of grazoprevir, is a marketed anti-HCV drug acting as a selective inhibitor of theHepatitis C Virus NS3/4A Proteasewith IC50 values of 7pM, 4pM, and 62pM for HCV genotype 1a, 1B, and 4 respectively. |
|
V3161 | Grazoprevir sodium salt | 1425038-27-2 | Grazoprevir sodium salt (MK5172; MK-5172), the sodium salt form of grazoprevir, is an inhibitor of theHepatitis C Virus NS3/4A Protease (IC50 = 7pM, 4pM, and 62pM for HCV genotype 1a, 1B, and 4 respectively) used in combination with the NS5A replication complex inhibitor elbasvir for HCV treatment. |
|
V52040 | GS-9256 | 1001094-46-7 | GS-9256 is a selective HCV (hepatitis C virus) NS3 protease inhibitor. |
|
V54235 | GSK2818713 | 1422484-32-9 | GSK2818713 is a novel hepatitis C NS5A complex inhibitor. |
|
V76305 | HBV-IN-18 | 2766688-73-5 | HBV (hepatitis B virus)-IN-18 (Compound 3) is an HBV (hepatitis B virus) capsid assembly modulator (CpAM) with EC50 of 2790 nM. |
|
V54220 | HCV Core Protein (107-114) | 160187-74-6 | HCV (hepatitis C virus) Core Protein (107-114) is the least immunogenic residue in the major linear HCV (hepatitis C virus) core region. |
|
V54221 | HCV Core Protein (59-68) | 160187-72-4 | HCV (hepatitis C virus) Core Protein (59-68) is a bioactive peptide containing residues 59-68 of the HCV (hepatitis C virus) core protein. |
|
V54226 | HCV NS4A Protein (18-40) (JT strain) | 188427-41-0 | HCV (hepatitis C virus) NS4A Protein (18-40) (JT strain) is an HCV (hepatitis C virus) NS4A peptide, consisting of 18-40 NS4A protein residues, which can improve the catalytic efficiency of NS3 protease. |
|
V54224 | HCV Peptide (131-140) | 160926-86-3 | HCV (hepatitis C virus) Peptide (131-140) is a bioactive peptide. |
|
V54230 | HCV Peptide (257-266) | 199533-16-9 | HCV (hepatitis C virus) Peptide (257-266) is a bioactive peptide. |
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
